Lichen Sclerosus Treatment Companies

ID: MRFR/Pharma/2912-HCR

200 Pages

Vikita Thakur

Last Updated: February 16, 2025

Lichen sclerosus is a chronic inflammatory skin condition that predominantly affects the genital and anal areas. The treatment for lichen sclerosus may involve the use of topical corticosteroids and other medications to manage symptoms and improve the quality of life for individuals with this condition. While there may not be specific companies exclusively focused on lichen sclerosus treatment, pharmaceutical companies that develop dermatological medications and therapies for inflammatory skin conditions may have products relevant to its management.

Lichen Sclerosus Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.89%

2024 Market Size$ 0.85 Billion

2025 Market Size$ 0.9 Billion

2035 Market Size$ 1.59 Billion

Key Players

AbbVie

Bristol-Myers Squibb

Eli Lilly and Company

Novartis

Pfizer

Sanofi

Trends

Rising Awareness and Education
Advancements in Therapeutic Options
Patient-Centric Approaches

Opportunities

Increased Focus on Women's Health
Innovations in Treatment Modalities
Rising Demand for Personalized Medicine

Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Lichen Sclerosus Treatment Market

Lichen Sclerosus Treatment Key Companies

Latest Lichen Sclerosus Treatment Companies Update

Invivio Therapeutics receives FDA Fast Track designation for LIT-100 for the treatment of Lichen Sclerosus: In September 2023, Invivio Therapeutics received Fast Track designation for LIT-100, a novel topical steroid foam formulation, highlighting its potential for addressing unmet needs in Lichen Sclerosus treatment.

Galderma launches Mirvaso (desmopressin) for the treatment of Lichen Sclerosus in adults: In June 2023, Galderma received FDA approval and launched Mirvaso, a nasal spray containing desmopressin, offering a non-steroidal option for managing Lichen Sclerosus symptoms.

Bayer announces Phase 2b trial results for JAK inhibitor for Lichen Sclerosus: In May 2023, Bayer announced positive Phase 2b trial results for its JAK inhibitor as a potential treatment for Lichen Sclerosus, indicating promising efficacy and safety profile.

List of Lichen Sclerosus Treatment Key Companies in the Market

AstraZeneca plc
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Johnson & Johnson Services Inc.
Merck & Co.Inc.
Pfizer Inc.
Sandoz AG (Novartis AG)
Sanofi S.A.
Valeant Pharmaceuticals
Zylera Pharmaceuticals

Customize Report

Certified Researchers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”